Our findings therefore add support to the clinical investigation of dual ALK/MEK inhibition therapy as a strategy to delay or overcome drug resistance in ALK-positive lung cancer, and points the way toward possible drug therapies with three or more targets. The gene discussed is MAP2K7; the disease is lung cancer.